ISIS Pharmaceuticals (ISIS): Q4 EPS of -$0.03. Revenue of $19.9M beats by $4.12M. (PR)


ISIS Pharmaceuticals (ISIS): Q4 EPS of -$0.03. Revenue of $19.9M beats by $4.12M. (PR)
From other sites
Comments (3)
  • arthurs1
    , contributor
    Comments (396) | Send Message
     
    2013 holds great promise for investors, but even more so for those with intractable diseases.
    28 Feb 2013, 08:47 AM Reply Like
  • mc10010
    , contributor
    Comments (196) | Send Message
     
    I followed and own ISIS for over 15 years. First time ever I fill their technology has become accepted. Now they have to take advantage of that acceptance and create valuable medicines.
    28 Feb 2013, 09:00 AM Reply Like
  • KValinoti
    , contributor
    Comments (8) | Send Message
     
    Isis will be treading water until the class action suit is resolved. I also believe Kynamro will not be the drug of choice to treat genetically high cholesterol, (Juxtipid appears to be better tolerated) so I will only get back into this stock when other drugs in the pipeline show promise.
    28 Feb 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs